Login

Financial Snapshot

Revenue
TTM
$62.82B
Gross Margin
TTM
70.67%
Net Income
TTM
$3.635B
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
79.64%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
$76.21B
Book Value
2026 Q1
$60.25B
Cash
2026 Q1
P/E
TTM
104.7
Free Cash Flow
TTM
$19.98B

Stock Price

Loading...
Market Cap: $380.57 Billion

About AbbVie Inc

AbbVie Inc (NYSE: ABBV) is a biopharmaceutical company that researches, develops, manufactures, and sells medicines and therapies across therapeutic areas on a global basis. Revenue is generated through the commercialization and sale of prescription pharmaceutical products, with commercial efforts organized by geographic region or therapeutic area. AbbVie operates as a single global business segment, as disclosed in its 10-K filed 2026-02-20, with a unified research and development and supply chain organization responsible for discovery, development, manufacturing, and product supply worldwide. The company is incorporated in Delaware and headquartered in Texas, and its common stock trades on the New York Stock Exchange.

Revenue model
Transactional sales of prescription medicines and therapies to patients and healthcare systems, organized commercially by geographic region or therapeutic area. AbbVie operates as a single reporting segment with no disclosed segment revenue breakdown in the available filing excerpts.
Products and services
Innovative medicines and therapies across multiple therapeutic areas. Specific product names and brand details are referenced in the 10-K filed 2026-02-20 under Item 7 and Item 1, but are not reproduced in sufficient detail in the available excerpts to enumerate here.
Customers and end markets
End markets are organized by geographic region and therapeutic area per the 10-K filed 2026-02-20. Specific customer types such as hospitals, pharmacies, or payers are not detailed in the available filing excerpts.
Value-chain role
Fully integrated biopharmaceutical company spanning drug discovery, research and development, manufacturing, supply chain, and commercial sales and marketing.
Geographic exposure
Global operations with commercial efforts organized by geographic region. Specific country or regional revenue breakdowns are referenced in Note 16 of the 10-K filed 2026-02-20 but are not reproduced in the available excerpts.

Source: SEC 10-K, filed 2026-02-20

Industry: Pharmaceutical Preparations Peers: Amgen Inc Gilead Sciences, Inc Moderna Inc Regeneron Pharmaceuticals Inc Vertex Pharmaceuticals Inc

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support